HLA-ABC Monoclonal Antibody (W6/32), FITC, eBioscience | Invitrogen 11-9983-42 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

HLA-ABC Monoclonal Antibody (W6/32), FITC, eBioscience

catalog :

11-9983-42

quantity :

100 Tests

price :

US 242

clonality :

monoclonal

host :

mouse

conjugate :

FITC

clone name :

W6/32

reactivity :

human

application :

immunocytochemistry, flow cytometry

more info or order :

Invitrogen product webpage

citations: 41

Published Application/Species/Sample/Dilution	Reference
flow cytometry; human	Di Pucchio T, Chatterjee B, Smed Sorensen A, Clayton S, Palazzo A, Montes M, et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol. 2008;9:551-7 pubmed publisher
	Kishton R, Patel S, Decker A, Vodnala S, Cam M, Yamamoto T, et al. Cancer genes disfavoring T cell immunity identified via integrated systems approach. Cell Rep. 2022;40:111153 pubmed publisher
	Omer B, Cardenas M, Pfeiffer T, Daum R, Huynh M, Sharma S, et al. A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunol Res. 2022;10:512-524 pubmed publisher
	Piekarska K, Urban Wójciuk Z, Kurkowiak M, Pelikant Małecka I, Schumacher A, Sakowska J, et al. Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activity. Nat Commun. 2022;13:856 pubmed publisher
	Sawasdee N, Wattanapanitch M, Thongsin N, Phanthaphol N, Chiawpanit C, Thuwajit C, et al. Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors. Int J Mol Med. 2022;49: pubmed publisher
	Lemaître F, Carmena Moratalla A, Farzam Kia N, Carpentier Solorio Y, Tastet O, Cleret Buhot A, et al. Capturing T Lymphocytes' Dynamic Interactions With Human Neural Cells Using Time-Lapse Microscopy. Front Immunol. 2021;12:668483 pubmed publisher
	Que Y, Zhang X, Liu Z, Zhao J, Pan Q, Wen X, et al. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. J Immunother Cancer. 2021;9: pubmed publisher
	Gong B, Zheng L, Lu Z, Huang J, Pu J, Pan S, et al. Mesenchymal stem cells negatively regulate CD4<sup>+</sup> T cell activation in patients with primary Sjögren syndrome through the miRNA‑125b and miRNA‑155 TCR pathway. Mol Med Rep. 2021;23: pubmed publisher
	Cabanes Creus M, Westhaus A, Navarro R, Baltazar G, Zhu E, Amaya A, et al. Attenuation of Heparan Sulfate Proteoglycan Binding Enhances In Vivo Transduction of Human Primary Hepatocytes with AAV2. Mol Ther Methods Clin Dev. 2020;17:1139-1154 pubmed publisher
	Sun Y, Ren Y, Yang F, He Y, Liang S, Guan L, et al. High-yield isolation of menstrual blood-derived endometrial stem cells by direct red blood cell lysis treatment. Biol Open. 2019;8: pubmed publisher
	Uchida E, Suwa S, Yoshimoto R, Watanabe K, Kasama T, Miura O, et al. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation. Int J Oncol. 2019;54:1785-1796 pubmed publisher
	Li M, Liu Z, Wang X. Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment. J Oncol. 2018;2018:3979527 pubmed publisher
	Lanuza P, Vigueras A, Oliván S, Prats A, Costas S, Llamazares G, et al. Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression. Oncoimmunology. 2018;7:e1395123 pubmed publisher
	Hammer A, Waschbisch A, Knippertz I, Zinser E, Berg J, Jörg S, et al. Role of Nuclear Factor (Erythroid-Derived 2)-Like 2 Signaling for Effects of Fumaric Acid Esters on Dendritic Cells. Front Immunol. 2017;8:1922 pubmed publisher
	Sethumadhavan S, Silva M, Philbrook P, Nguyen T, Hatfield S, Ohta A, et al. Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells. PLoS ONE. 2017;12:e0187314 pubmed publisher
	Haworth K, Arnold M, Pierson C, Choi K, Yeager N, Ratner N, et al. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017;8:82037-82048 pubmed publisher
	Fuchi N, Miura K, Doi H, Li T, Masuzaki H. Feasibility of placenta-derived mesenchymal stem cells as a tool for studying pregnancy-related disorders. Sci Rep. 2017;7:46220 pubmed publisher
	Geiger R, Rieckmann J, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell. 2016;167:829-842.e13 pubmed publisher
	Camilleri E, Gustafson M, Dudakovic A, Riester S, Garces C, Paradise C, et al. Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Res Ther. 2016;7:107 pubmed publisher
	Abrahimi P, Qin L, Chang W, Bothwell A, Tellides G, Saltzman W, et al. Blocking MHC class II on human endothelium mitigates acute rejection. JCI Insight. 2016;1: pubmed
	Concha Benavente F, Srivastava R, Trivedi S, Lei Y, Chandran U, Seethala R, et al. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNÎ³ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res. 2016;76:1031-43 pubmed publisher
	Yuan D, Xia M, Meng G, Xu C, Song Y, Wei J. Anti-angiogenic efficacy of 5'-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs. Oncotarget. 2015;6:29664-74 pubmed publisher
	Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsumoto Y, et al. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med. 2015;4:1322-33 pubmed publisher
	SÃ¡nchez MartÃnez D, Azaceta G, Muntasell A, AguilÃ³ N, NÃºÃ±ez D, GÃ¡lvez E, et al. Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells. Oncoimmunology. 2015;4:e991613 pubmed
	Abrahimi P, Chang W, Kluger M, Qyang Y, Tellides G, Saltzman W, et al. Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9. Circ Res. 2015;117:121-8 pubmed publisher
	Mimura K, Kua L, Shiraishi K, Kee Siang L, Shabbir A, Komachi M, et al. Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-? treatment. Cancer Sci. 2014;105:1236-44 pubmed publisher
	Fernandez I, Ooi T, Roy K. Generation of functional, antigen-specific CD8+ human T cells from cord blood stem cells using exogenous Notch and tetramer-TCR signaling. Stem Cells. 2014;32:93-104 pubmed publisher
	Meng G, Xia M, Xu C, Yuan D, Schnurr M, Wei J. Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation. Int J Cancer. 2014;134:1958-71 pubmed publisher
	Riolobos L, Hirata R, Turtle C, Wang P, Gornalusse G, Zavajlevski M, et al. HLA engineering of human pluripotent stem cells. Mol Ther. 2013;21:1232-41 pubmed publisher
	Krupa A, Fudala R, Florence J, Tucker T, Allen T, Standiford T, et al. Bruton's tyrosine kinase mediates Fc?RIIa/Toll-like receptor-4 receptor crosstalk in human neutrophils. Am J Respir Cell Mol Biol. 2013;48:240-9 pubmed publisher
	Pennino D, Bhavsar P, Effner R, Avitabile S, Venn P, Quaranta M, et al. IL-22 suppresses IFN-?-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol. 2013;131:562-70 pubmed publisher
	Andres A, Dennis M, Kretzschmar W, Cannons J, Lee Lin S, Hurle B, et al. Balancing selection maintains a form of ERAP2 that undergoes nonsense-mediated decay and affects antigen presentation. PLoS Genet. 2010;6:e1001157 pubmed publisher
	Graef T, Moesta A, Norman P, Abi Rached L, Vago L, Older Aguilar A, et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med. 2009;206:2557-72 pubmed publisher
	Matsuo Y, Masutani H, Son A, Kizaka Kondoh S, Yodoi J. Physical and functional interaction of transmembrane thioredoxin-related protein with major histocompatibility complex class I heavy chain: redox-based protein quality control and its potential relevance to immune responses. Mol Biol Cell. 2009;20:4552-62 pubmed publisher
	Price C, Hassi H, English N, Blakemore A, Stagg A, Knight S. Methylglyoxal modulates immune responses: relevance to diabetes. J Cell Mol Med. 2010;14:1806-15 pubmed publisher
	Li J, Srivastava T, Rawal R, Manuel E, Isbell D, Tsark W, et al. Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development. Virology. 2009;387:16-28 pubmed publisher
	Sanjanwala B, Draghi M, Norman P, Guethlein L, Parham P. Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1. J Immunol. 2008;181:6293-300 pubmed
	Koene G, Arts Hilkes Y, van Dijk A, van der Ven K, Slootweg P, de Weger R, et al. High level of aneuploidy of chromosome 6 by FISH analysis of head and neck squamous cell carcinoma: limited applicability of LOH analysis to define HLA loss. Hum Immunol. 2004;65:1455-62 pubmed
	Wu Q, Jinde K, Endoh M, Sakai H. Clinical significance of costimulatory molecules CD80/CD86 expression in IgA nephropathy. Kidney Int. 2004;65:888-96 pubmed
	Goldman Wohl D, Ariel I, Greenfield C, Hochner Celnikier D, Lavy Y, Yagel S. A study of human leukocyte antigen G expression in hydatidiform moles. Am J Obstet Gynecol. 2001;185:476-80 pubmed
	Stern P, Beresford N, Friedman C, Stevens V, Risk J, Johnson P. Class I-like MHC molecules expressed by baboon placental syncytiotrophoblast. J Immunol. 1987;138:1088-91 pubmed

product information

Product Type :

Antibody

Product Name :

HLA-ABC Monoclonal Antibody (W6/32), FITC, eBioscience

Catalog # :

11-9983-42

Quantity :

100 Tests

Price :

US 242

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: 5 µL (1 µg)/test, Immunocytochemistry: 5 µg/mL

Species :

Human

Clone :

W6/32

Isotype :

IgG2a, kappa

Storage :

4° C, store in dark, DO NOT FREEZE!

Description :

HLA-class I major histocompatibility (MHC) antigens are intrinsic membrane glycoproteins expressed on nucleated cells and noncovalently associated with an invariant beta2 microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumor defense. Human HLA-class I antigens are represented by HLA-A, HLA-B and HLA-C molecules. HLA and MHC antibodies play a significant role in Immunopeptidomics, facilitating the identification and characterization of neoantigens through high-performance liquid chromatography coupled to tandem Mass Spectrometry.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 5 µL (1 µg)/test, Immunocytochemistry: 5 µg/mL

Aliases :

A29 protein; alpha chain of MHC class II; antigen presenting molecule; AS; Aw-33; Aw-74; B-4901; B-5001; Bw-47; Bw-50; class I MHC, HLA-B antigen; D6S204; epididymis secretory protein Li 83; H-2K; H2-K; H-2K(d); HEL-S-83; histocompatibility antigen; HLA A; HLA -B; HLA B-40011; HLA B44; HLA C; HLA class I antigen; HLA class I antigen HLA-B; HLA class I histocompatibility antigen C alpha chain; HLA class I histocompatibility antigen Cw-1 alpha chain; HLA class I histocompatibility antigen, A alpha chain; HLA class I histocompatibility antigen, A-1 alpha chain; HLA class I histocompatibility antigen, A-11 alpha chain-like; HLA class I histocompatibility antigen, A-30 alpha chain; HLA class I histocompatibility antigen, A-33 alpha chain; HLA class I histocompatibility antigen, A-74 alpha chain; HLA class I histocompatibility antigen, B alpha chain; HLA class I histocompatibility antigen, B-47 alpha chain; HLA class I histocompatibility antigen, B-50 alpha chain; HLA class I histocompatibility antigen, B-82 alpha chain; HLA class I histocompatibility antigen, C alpha chain; HLA class I histocompatibility antigen, Cw-1 alpha chain; HLA class I histocompatibility antigen, Cw-15 alpha chain; HLA class I histocompatibility antigen, Cw-18 alpha chain; HLA locus; HLA molecule; HLAA; HLA-A; HLA-A locus alpha 2 domain; HLA-A null; HLA-A11; HLA-A33; HLA-Aw33.1; HLAB; HLA-B; HLA-B 1502; HLA-B alpha chain; HLA-B alpha chain (B*2706); HLA-B alpha chain (B*5002); HLA-B alpha-chain; HLA-B*45ZJ; HLA-B15; HLA-B35; HLA-B35 antigen; HLA-B-3506; HLA-B39; HLA-B-3905; HLA-B49; HLA-B50; HLA-B55; HLA-B-5502; HLA-B-5602; HLA-B59; HLA-B61; HLA-Bw50 antigen; HLAC; HLA-C; HLA-C alpha chain; HLA-C alpha chain (HLA-Cw*15v); HLA-C alpha chain for Cw*18GB; HLA-C alpha-chain; HLA-C antigen; HLA-Cw; HLA-Cw*04GB; HLA-Cw*1702; HLA-Cw*18GB; HLA-Cw-1503; HLA-DQB1; HLA-DRB1; HLA-JY3; HLC-C; Human leukocyte antigen A; Human leukocyte antigen C; human leukocyte antigen-C alpha chain; hypothetical protein; lecocyte antigen B; leucocyte antigen A; Leukocyte Antigen; leukocyte antigen C; leukocyte antigen class I-A; leukocyte antigen class I-B; Leukoocyte Antigen; LOC100515902; LOW QUALITY PROTEIN: HLA class I histocompatibility antigen, A-11 alpha chain-like; lymphocyte antigen; major histocompatability complex B antigen; major histocompatibility antigen HLA-C; major histocompatibility complex, class I, A; major histocompatibility complex, class I, B; major histocompatibility complex, class I, C; MCH class I antigen; MGC184092; MGC7052; MHC; MHC 1; MHC antigen; MHC clas I antigen; MHC Class 1; MHC class 1 antigen; MHC class I; MHC class I alpha chain; MHC class I anitgen; MHC class I anti; MHC Class I antigen; MHC class I antigen A*30; MHC class I antigen A*33; MHC class I antigen A*74; MHC class I antigen B*47; MHC class I antigen B*50; MHC class I antigen B*82; MHC class I antigen Cw*15; MHC class I antigen Cw*18; MHC class I antigen GN00104; MHC class I antigen heavy chain; MHC class I antigen heavy chain HLA-C; MHC class I antigen HLA-A heavy chain; MHC class I antigen HLA-A33; MHC class I antigen HLA-B alpha chain; MHC class I antigen HLA-B heavy chain; MHC class I antigen null protein; MHC class I antigen SHCHA; MHC class I antigene; MHC class I histocompatibility antigen; MHC class I human leukocyte antigen; MHC class I molecule; MHC class I protein; MHC class II antigen; MHC class l antigen; MHC classI antigen; MHC HLA-ABC; MHC HLA-B cell surface glycoprotein; MHC HLA-B transmembrane glycoprotein; MHC HLA-B27d; MHC HLA-B27-HS; MHC HLA-B39N; MHC I HLA; MHC1; PSORS1; SPDA1; surface antigen; truncated class I antigen; truncated MHC class I antigen

more info or order :

Invitrogen product webpage